Hens, M., Vaidyanathan, G., Welsh, P. and Zalutsky, M.R. (2009) Labeling Internalizing Anti-Epidermal Growth Factor Receptor Variant III Monoclonal Antibody with 177Lu: In Vitro Comparison of Acyclic and Macrocyclic Ligands. Nuclear Medicine and Biology, 36, 117-128.
http://dx.doi.org/10.1016/j.nucmedbio.2008.11.001

has been cited by the following article:

• TITLE: Radiolanthanides Device Production

  AUTHORS: F. Monroy-Guzman, F. Jimenez Barreiro, E. Jaime Salinas, A. L. Vera Treviño

  KEYWORDS: 149Pm, 161Tb, 166Ho, 177Lu, Production

  JOURNAL NAME: World Journal of Nuclear Science and Technology, Vol.5 No.2, April 28, 2015

  ABSTRACT: 149Pm, 166Ho, 161Tb and 177Lu conjugated to chemical agents (monoclonal antibodies, polypeptide, etc.) have the appropriate decay characteristics for imaging and therapeutic studies and consequently the potential to be useful in radiotherapy and diagnosis. These carrier-free radioisotopes can be produced by neutron irradiation of a lanthanide target followed by β-decay, and a posterior radiochemical separation of the daughter radionuclide from macro-amounts of the parent target. In order to produce carrier free 149Pm, 161Tb, 166Ho and 177Lu for radiotherapy, with a radionuclide purity of more than 99.9%, a device production was developed based on separation of Nd/Pm, Gb/Tb, Dy/Ho and Yb/Lu by extraction chromatography.